Novoroo Bioscience

Novoroo Bioscience is a pre-clinical stage biotechnology company focused on the development of small molecule therapeutics designed to enhance the activity of the proteasome. The company’s approach centers on the activation of the 20S proteasome to promote the degradation of toxic, misfolded proteins associated with neurodegenerative disorders. By leveraging structural biology expertise, Novoroo aims to restore proteostasis and provide disease-modifying treatments for conditions such as Alzheimer’s and Parkinson’s diseases. Founded as a spin-out from the University of Utah, the company utilizes proprietary insights into proteasome dynamics to develop high-potency oral medications. Their platform targets the underlying protein aggregation that characterizes several high-unmet-need neurological indications.